Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P30793
UPID:
GCH1_HUMAN
Alternative names:
GTP cyclohydrolase I
Alternative UPACC:
P30793; Q6FHY7; Q9Y4I8
Background:
GTP cyclohydrolase 1, also known as GTP cyclohydrolase I, plays a pivotal role in the biosynthesis of tetrahydrobiopterin (BH4), a critical cofactor in the production of neurotransmitters such as dopamine and serotonin. This enzyme's activity is essential in various physiological processes, including nitric oxide synthesis in endothelial cells and potentially in modifying pain sensitivity.
Therapeutic significance:
The enzyme's deficiency is linked to diseases such as Hyperphenylalaninemia, BH4-deficient, B, characterized by severe neurological symptoms, and Dopa-responsive dystonia, a movement disorder alleviated by L-DOPA treatment. Understanding GTP cyclohydrolase 1's role could lead to novel therapeutic strategies for these conditions.